Signify Premium Insight: The Concerted Effort that TeraRecon Must Make

Written by Alan Stoddart

Published: April 26, 2022

TeraRecon first became linked to ConcertAI after being acquired by corporate parent SymphonyAI in March 2020. This portfolio of companies seeking to develop new generation AI solutions across a variety of sectors, from retail to financial services, brought TeraRecon on board and placed it alongside stablemate ConcertAI. At the time the deal seemed to offer clear synergistic opportunities for both parties such combining population data from ConcertAI with imaging biomarker technology and expertise to improve patient stratification for oncology clinical trials. Alternatively, providers could utilise imaging data from TeraRecon alongside EHRs and real-world data from ConcertAI to develop more integrated care management solutions.

Already have an account? Sign in here

Related Report

Imaging IT – Market Intelligence Service

Ongoing series of reports, data and insights delivered over the year

Imaging IT – Market Intelligence Service

This Market Intelligence Service is an annual subscription that provides ongoing data, insights and analysis on the global opportunities for Imaging IT.

Find out more